Introduction
TME and therapeutic resistance in TNBC
Remodeling of the TME
The phytochemicals remodel TME
Gut microbiota activate anti-tumor immunity
IFNs activate anti-tumor immunity
Targeting immunotherapy resistance in TNBC
p53 delivery combined with PD-1 inhibitors
CXCR2 inhibitor combined with ICIs
PmTriTNE@CDA nanotechnology
ICI monotherapy
Anti-PD-1/PD-L1 therapy
Anti-CTLA-4 therapy
Combination of two ICIs
Combination of ICIs and other treatments
ICIs combined with chemotherapy
ICIs combined with radiotherapy
ICIs combined with gene therapy
ICIs combined with targeted therapy
ICIs combined with poly (adenosine diphosphate ribose) polymerase inhibitors
ICIs combined with anti-angiogenic drugs
ICIs combined with PI3K/AKT pathway inhibitors and chemotherapy
ICIs combined with 2-fluoro-L-focus (2 F-Fuc)
ICIs combined with nanotechnology
ICIs combined with recombinant nanoparticles
ICIs combined with Mucin 1 messenger RNA nanovaccine
Tumor vaccine
Adagloxad simolenin
α- lactalbumin engineered vaccine
DR5 DNA vaccine
DC fusion vaccine
Personalized peptide vaccine
Cellular immunotherapy
Chimeric antigen receptor T cell therapy
NK cell therapy
Cytokine-induced killer cell therapy
Bispecific antibody approaches for TNBC therapy
Trial number | Treatment | Subject | Results in patients with TNBC | Refs |
---|---|---|---|---|
NCT02447003 | Pembrolizumab | Metastatic TNBC | ORR in ITT: 5.3%; ORR in patients with PD-L1+: 5.7%; mPFSb : 2.0 m; mOSb : 9.0 m | [54] |
KEYNOTE-012 | Pembrolizumab | Metastatic TNBC | ORR: 18.5%; mPFS: 1.9 m; mOS: 11.2 m | [53] |
NCT01375842 | Atezolizumab | Metastatic TNBC | ORR in ITT: 10.0%; ORR in patients with PD-L1+: 12.0%; mPFSb: 1.4 m; mOSb : 8.9 m | [58] |
NCT01772004 | Avelumab | Metastatic TNBC | ORR in ITT: 5.2%; ORR in patients with PD-L1+: 44.0%; mPFSb : 1.4 m; mOSb : 9.2 m | [59] |
NCT02838823 | JS001 | Metastatic TNBC | ORR in ITT: 5.0%; ORR in patients with PD-L1+: 11.1%; ORR in patients with PD-L1– tumours: 0%; mPFSb : 1.8 m | [57] |
NCT02447003 | Pembrolizumab | Metastatic TNBC | ORR: 21.4%; mPFS: 2.1 mo; mOS: 18 m | [162] |
Durvalumab + Tremelimumab | Metastatic TNBC | Induce plasma cells to produce specific antibodies, Activated and Increased T cell | [66] | |
NCT02657889 | Pembrolizumab + Niraparib | Advanced/metastatic TNBC | ORR 21%, DCR 49% | [94] |
NCT03330405 | ICIs + Avelumab + Talazoparib | Advanced TNBC | ORR = 18.2% | [95] |
NCT0265788 | Niraparib + Pembrolizumab | Advanced/Metastatic TNBC | ORR in ITT: 29.0%; ORR in patients with PD-L1 + tumors 32% | [94] |
NCT03394287 | Camrelizumab + VEGFR2 inhibitors | Advanced TNBC | shown good efficacy in patients with PD-L1 negative tumors or those receiving advanced lines of chemotherapy | [100] |
NCT02555657 | Pembrolizumab vs. TPCe | Metastatic TNBC | ORR in patients with CPS ≥ 10: 17.7% vs. 9.2%; mPFS in patients with CPS ≥ 10: 2.1 mo vs. 3.4 m; mOS in patients with CPS ≥ 10: 12.7 m vs. 11.6 m (P = 0.06) | [163] |
NCT03310957 | Ladiratuzumab vedotin + Pembrolizumab | Metastatic TNBC | ORR: 54.0% | [164] |
NCT03742102 | Durvalumab + Trastuzumab deruxtecan | Metastatic TNBC | ORR: 66.7% | [165] |
NCT02513472 | Eribulin + Pembrolizumab | Metastatic TNBC | ORR overall: 23.4%; ORR in patients with PD-L1 + tumors, first-line setting: 34.5%; | [166] |
NCT02734004 | Olaparib + Durvalumab | Metastatic TNBC | ORR: 58.8%; mPFS: 4.9 m; mOS: 20.5 m | [96] |
NCT03752723 | GX-I7 + Pembrolizumab | Metastatic TNBC | ORR: 13.3% | [167] |
NCT02708680 | Entinostat + Atezolizumab | Metastatic TNBC | ORR: 10.0%; mPFS: 1.68 m; mOS: 9.4 m | [107] |
NCT03797326 | Lenvatinib + Pembrolizumab | Metastatic TNBC | ORR: 29.0% | [168] |
NCT02819518 | TPCg + Pembrolizumab/Placebo | Metastatic TNBC | ORR (co-primary end point) in patients with CPS > 10: 53.2% vs. 39.8% | |
NCT01042379 | Paclitaxel with or without Pembrolizumab + adjuvant chemotherapy | Early-stage TNBC | pCR rate: 60% vs. 22% | [170] |
NCT02685059 | Nab-paclitaxel + Durvalumab/Placebo +Endocrine therapy +Durvalumab/Placebo | Early-stage TNBC | pCR rate in ITT: 53.4% vs. 44.2% (P = 0.29); pCR rate in patients with PD-L1 + on IC: 58.0% vs. 50.7% | |
NCT02622074 | Pembrolizumab + Anthracycline + Taxane-based Chemotherapy with or without Carboplatin + Adjuvant chemotherapyc | Early-stage TNBC | pCR rate overall: 60%; pCR rate in patients with CPS > 1: 64%; pCR rate in patients with CPS > 30: 72% | [72] |
NCT03197935 | Nab-paclitaxel + Atezolizumab /Placebo + Adjuvant chemotherapy+ Atezolizumab/Placebo | Early-stage TNBC | pCR rate in ITT: 58% vs. 41% (P = 0.004); pCR rate in patients with PD-L1 + on IC: 69% vs. 49% (P = 0.02); | [78] |
NCT03036488 | Anthracycline, taxane and carboplatin-based chemotherapy + Pembrolizumab/Placebo + Adjuvant Chemotherapy/Endocrine therapy | Early-stage TNBC | pCR rate: 63.0% vs. 55.6% | [73] |
NCT02620280 | Nab-paclitaxel + Carboplatin with or without Atezolizumab | Early-stage TNBC | pCR rate in ITT: 43.5% vs. 40.8%; pCR rate in patients with PD-L1 + on IC: 51.9% vs. 48.0% | [77] |
NCT02819518 | Pembrolizumab + Chemotherapy | Advanced TNBC | mOS was higher than placebo-chemotherapy group | [80] |
NCT01633970 | Nab-paclitaxel +Atezolizumab | Metastatic TNBC | ORR in ITT: 39.4%; mPFSb : 5.5 m; mOSb : 14.7 m | [171] |
NCT03800836 | Ipatasertib + Atezolizumab + Paclitaxel/ Nab-paclitaxel | Metastatic TNBC | ORR in ITT: 73.0%; ORR in patients with PD-L1 + tumors: 82% | [105] |
NCT04129996 | Angiogenesis inhibitor + Camrelizumab + Chemotherapy | Advanced immunomodulatory TNBC patients | objective response rate was 81.3%, mPFS was 13.6 m, PFS was higher in CD8 + than in CD8- patients | [101] |
NCT02322814 | Cobimetinib + Atezolizumab +Paclitaxel/Nab-paclitaxel | Metastatic TNBC | ORR overall: 31.7%; ORR in patients with PD-L1 + tumors: 44% with paclitaxel, 33% with nab-paclitaxel | [108] |
NCT02425891 | Nab-paclitaxel + Atezolizumab/Placebo | Metastatic TNBC | ORR in ITT: 56.0% vs. 45.9% (P = 0.002); ORR in patients with PD-L1 + tumors: 58.9% vs. 42.6% (P = 0.002) | [172] |
NCT03125902 | Paclitaxel + Atezolizumab/Placebo | Metastatic TNBC | ORR in ITT: 53.6 vs. 47.5; ORR in patients with PD-L1 + tumors: 63.4% vs. 55.4% | [173] |
NCT02299999 | Durvalumab vs. Chemotherapy | Metastatic TNBC | mOS in all patients with TNBC: 21.2 m vs. 14 m (P = 0.04); mOS in patients with PD-L1 + tumors: 27.3 m vs. 12.1 m (P = 0.07) | [174] |
NCT04674306 | α- lactalbumin engineered vaccine | TNBC | Ongoing | [121] |
NCT03562637 | Adagloxad Simolenin(OBI-822/OBI-821) | High risk early Globo-H positive TNBC | Longer PFS in vaccinated patients who developed anti-Globo H (anti-GH) IgG | [120] |
NCT02427581 | Personalized peptide vaccine | Metastatic and recurrent TNBC | 1/18 patients developed a complete and partial immune response | [125] |
NCT01395056 | cytokine-induced killer cell (CIK) infusion + chemotherapy | Post-mastectomy TNBC/TNBC | Prevented disease recurrence and prolong survival, | [142] |
Treatment | Treatment mechanism | in vitro or in vivo | Result | Refs |
---|---|---|---|---|
Rg3 liposome + Docetaxel | Inhibited TGF-β secretion, reduced CAFs and collagens | 4T1 mice model | improve the anti-tumor effect of DTX | [24] |
Anacardic acid(6SA) | Activate immune cells, augment the secretion of IFN-γ and TNF-α, and improve TME | 4T1 mice model | Induced cell apoptosis, reduced tumor volume | [27] |
CpG-oligodeoxynucleotides | Combined with anti PD-1 inhibitors, stimulated plasmacytoid DCs to produce IFN α and β | TNBC mice | Upregulated IFN release; increase antigen-specific CD8 + T cell infiltration | [37] |
Radiotherapy + ICIs | Upregulated the expression of genes containing immunogenic mutations, induced CD8 + and CD4 + T cells | Low immunogenicity TNBC mice | Enhanced anti-tumor efficacy | [84] |
Radiotherapy + anti-PD-1 antibody | Reduced tumor cell growth not only in the irradiated site but also in non-irradiated sites | Poorly immunogenic metastatic 4T1 mice | Reduced tumor cell growth, improved survival rates, and inhibited lung metastasis | [85] |
AdLyp.sT and mHAdLyp.sT | Expressed sTGFβRIIFc that inhibit TGFβ pathways, enhanced the efficacy of anti- CTLA-4 and anti-PD-1 | 4T1 mice model | Inhibited tumor growth and metastases, augmented anti-PD-1 and anti-CTLA-4 therapy | [89] |
Albumin nanoparticle | Contain PI3K-γ inhibitor eganelisib (IPI-549) and PTX | TNBC mice | Enhanced the efficacy of α-PD1 with longer PFS and a better remission rate | [104] |
2 F-Fuc + anti-PD-L1 | Enhance the activation of T cells, blocked B7H3 core focusing | TNBC mice | Significantly inhibited tumor growth | [106] |
ICD + PD-1/PD-L1 blockade + iPPO + MW | Facilitated the maturation of DCs and reversed the immunosuppressive environment | 4T1 mice model | Amplified the systemic anti-tumor immune response | [114] |
mEHGZ + anti-PD-L1 | Induced IFN-γ and CD8 + T cell infiltration | 4T1 mice model | Enhanced the sensitivity and efficacy of ICIs | [115] |
Nanoparticles (NPs) | Delivered an mRNA vaccine encoding tumor antigen MUC1 to DCs to activate and expand tumor-specific T cells | 4T1 mice model | NPs improved the stability, sustainability, and expression level of messenger RNA-based vaccines | [117] |
BiTP (Anti-TGF-β/PD-L1 bispecific antibody) | Effectively counteracted TGF-β-Smad, PD-L1, PD-1 penetration, increased TIL NFAT signaling, decreased collagen deposition, enhanced CD8 T cell | Cell, TNBC mice models | Superior antitumor activity relative to anti-PD-L1 and anti-TGF-β monotherapy | [175] |
α-lactalbumin engineered vaccine | α- lactalbumin specific T cells induce tumor inflammation and cytotoxicity | 4T1 mice model | Boosted antitumor immunity, provide significant protection and therapy against growth of autochthonous tumors in MMTV-neu and MMTV-PyVT transgenic mice and against 4T1 transplantable tumors | [121] |
TMAO | Remodel of the TME | 4T1 mice model/cell | Enhanced the infiltration and killing function of CD8 + T cells, induce tumor cell pyrosis | [29] |
Rg3 + paclitaxel | Inhibit NF-κB activation, decreased NF-κB p65 and Bcl-2 protein expressions, increased Bax and Caspase-3 protein expressions | MDA-MB-231 cell | Rg3 promoted cytotoxicity and apoptosis of Paclitaxel | [25] |
Pos3Aa-p53 | Enhance the sensitivity to the chemotherapy drug 5-fluorouracil | TNBC mice, MDA-MB-231、549、4T1 cell | Resulted in the restoration of p53 function in p53-deficient cancer cells, and sensitized them to 5-fluorouracil chemotherapy | [42] |
AZD5069 + Atezolizumab | Reduce chemoresistance | MDA-MB-231 cell | Enhanced the efficacy of anti-PD-L1 therapy | [45] |
PmTriTNE@CDA | Upregulate the expression of type I IFNs | 4T1 and MDA-MB-231 cell | Improved immunogenicity | [46] |
Pos3Aa-p53 +anti-PD-1 antibodies | Induce anti-tumor immune memory | Mouse 4T1 breast cancer cells | Enhanced clinical response to anti-PD-1 therapy | [43] |
Ad.sTbetaRFc | High levels of viral replication | MDA-MB-231cell | More than 85% of the tumors showed reduction | [87] |
DR5 DNA vaccine | induced DR5-specific T cells to secrete IFN-γ | BALB/c mouse model | Triggered tumor cell apoptosis | [122] |
DC fusion vaccine | increased levels of IL-12 and IFN-γ | 4T1 mice model, Mouse 4T1 breast cancer cells | Had specific cytotoxic effect on tumor cells | [123] |
Chimeric antigen receptor T cell therapy | delivery of CAR T cells in fibrin gel applied into the resected tumor cavity | TNBC mouse model, MDA-MB-231 | Significantly eliminated residual tumor cells in mice TNBC models | [128] |
MUC28z CAR-T cells | Increased production of Granzyme B, IFN-γ and other Th1 type cytokines and chemokines | TNBC cell, breast cancer mouse model | Inhibited the growth of TNBC tumors in-vivo and in-vitro conditions | [127] |
Ruthenium complexes + Aptamer-engineered approaches | Induce robust ROS generation, activate multiple apoptosis-related receptors, enhance the sensitivity of TNBC to NK cell therapy | MDA-MB-231 cells | Modulated the immune microenvironment | [136] |
Repeated administration of CIK cells and cetuximab | Foster potent antibody-dependent cell–mediated cytotoxicity (ADCC) | MDA-MB-231 cells, TNBC mouse model | Significantly impede the growth, metastasis, and dissemination of TNBC cells and xenotransplanted tumors in lymph nodes and lung | [176] |
Atezolizumab +FAK inhibitors | Potentiates T cell-mediated cytotoxicity and significantly enhance the inhibitory effects of FAK inhibitors | TNBC cells | Suppressed TNBC cell invasion and motility | [143] |
FAK inhibitor + CIK cells | FAK suppression promote cytotoxicity induced by CIK cells | MDA-MB-231 cell, TNBC mouse model | Significantly suppressed tumor growth than the treatment of FAK inhibitor or CIK cells alone | [145] |
Anti-TROP2xCD3 bispecific antibody F7AK3 | F7AK3 recruits T cells to TROP2 tumor cells | TNBC cells, Mouse TNBC xenograft model | Inhibited the TNBC tumor growth | [146] |
MesobsFab | facilitates the recruitment and infiltration of NK cells into tumor sphere | TNBC cell, mouse model | Potent dose-dependent cell-mediated cytotoxicity | [177] |